Literature DB >> 20306313

FOXP3+ cell density in primary tumor has no prognostic impact in patients with cutaneous malignant melanoma.

Andrea Ladányi1, Anita Mohos, Beáta Somlai, Gabriella Liszkay, Katalin Gilde, Zsuzsanna Fejos, István Gaudi, József Tímár.   

Abstract

Regulatory T cells (Tregs) have been implicated as inhibitors of antitumor immune reactions. However, data on the relevance of their prevalence at tumor sites in influencing disease outcome are controversial. The aim of our study was to investigate the role in tumor progression and the prognostic impact of the density of lymphocytes expressing FOXP3, a transcription factor expressed predominantly by CD4(+)CD25(+) Tregs, in primary cutaneous melanoma. We examined the infiltration of FOXP3(+) cells by immunohistochemistry in tumor samples from 97 patients and evaluated in relation to patient and tumor parameters. The degree of infiltration by FOXP3(+) cells did not show correlation with the thickness of melanomas. Moreover, no associations were found with metastasis formation during the 5-year follow-up period, patient survival, or any other clinicopathologic parameters studied. These results suggest that the presence of FOXP3(+) lymphocytes in primary tumors is not of prognostic importance in human cutaneous melanoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20306313     DOI: 10.1007/s12253-010-9254-x

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  37 in total

Review 1.  Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance.

Authors:  F M Marincola; E M Jaffee; D J Hicklin; S Ferrone
Journal:  Adv Immunol       Date:  2000       Impact factor: 3.543

2.  Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions.

Authors:  Nobuyoshi Hiraoka; Kaoru Onozato; Tomoo Kosuge; Setsuo Hirohashi
Journal:  Clin Cancer Res       Date:  2006-09-15       Impact factor: 12.531

3.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

4.  Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells.

Authors:  Tomás Alvaro; Marylène Lejeune; Ma Teresa Salvadó; Ramón Bosch; Juan F García; Joaquín Jaén; Alison H Banham; Giovanna Roncador; Carlos Montalbán; Miguel A Piris
Journal:  Clin Cancer Res       Date:  2005-02-15       Impact factor: 12.531

5.  Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.

Authors:  Qiang Gao; Shuang-Jian Qiu; Jia Fan; Jian Zhou; Xiao-Ying Wang; Yong-Sheng Xiao; Yang Xu; Yi-Wei Li; Zhao-You Tang
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

Review 6.  Identification of tumor antigens and T-cell epitopes, and its clinical application.

Authors:  Annette Paschen; Stefan Eichmuller; Dirk Schadendorf
Journal:  Cancer Immunol Immunother       Date:  2003-12-20       Impact factor: 6.968

7.  Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells.

Authors:  Mindi R Walker; Deborah J Kasprowicz; Vivian H Gersuk; Angele Benard; Megan Van Landeghen; Jane H Buckner; Steven F Ziegler
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

8.  FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis.

Authors:  Noritoshi Kobayashi; Nobuyoshi Hiraoka; Wataru Yamagami; Hidenori Ojima; Yae Kanai; Tomoo Kosuge; Atsushi Nakajima; Setsuo Hirohashi
Journal:  Clin Cancer Res       Date:  2007-02-01       Impact factor: 12.531

9.  Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production.

Authors:  Sarah E Allan; Sarah Q Crome; Natasha K Crellin; Laura Passerini; Theodore S Steiner; Rosa Bacchetta; Maria G Roncarolo; Megan K Levings
Journal:  Int Immunol       Date:  2007-02-27       Impact factor: 4.823

10.  The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs.

Authors:  Sarah E Allan; Laura Passerini; Rosa Bacchetta; Natasha Crellin; Minyue Dai; Paul C Orban; Steven F Ziegler; Maria Grazia Roncarolo; Megan K Levings
Journal:  J Clin Invest       Date:  2005-10-06       Impact factor: 14.808

View more
  19 in total

Review 1.  Regulatory T cells in the immunotherapy of melanoma.

Authors:  Zhengxiao Ouyang; Hongwei Wu; Linqin Li; Yi Luo; Xianan Li; Gang Huang
Journal:  Tumour Biol       Date:  2015-10-30

2.  Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma.

Authors:  Sarah A Weiss; Sung Won Han; Kevin Lui; Jeremy Tchack; Richard Shapiro; Russell Berman; Judy Zhong; Michelle Krogsgaard; Iman Osman; Farbod Darvishian
Journal:  Hum Pathol       Date:  2016-07-26       Impact factor: 3.466

Review 3.  Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma.

Authors:  Nicolas Jacquelot; Jonathan M Pitt; David P Enot; Maria Paula Roberti; Connie P M Duong; Sylvie Rusakiewicz; Alexander M Eggermont; Laurence Zitvogel
Journal:  Oncoimmunology       Date:  2017-03-07       Impact factor: 8.110

Review 4.  The immune contexture in human tumours: impact on clinical outcome.

Authors:  Wolf Herman Fridman; Franck Pagès; Catherine Sautès-Fridman; Jérôme Galon
Journal:  Nat Rev Cancer       Date:  2012-03-15       Impact factor: 60.716

5.  Dinitrophenyl hapten with laser immunotherapy for advanced malignant melanoma: A clinical study.

Authors:  Dian-Jun Chen; Xiao-Song Li; Hui Zhao; Yan Fu; Huan-Rong Kang; Fang-Fang Yao; Jia Hu; Nan Qi; Huan-Huan Zhang; Nan Du; Wei-R Chen
Journal:  Oncol Lett       Date:  2016-12-23       Impact factor: 2.967

Review 6.  The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy.

Authors:  Daniela Bruni; Helen K Angell; Jérôme Galon
Journal:  Nat Rev Cancer       Date:  2020-08-04       Impact factor: 60.716

7.  Clinical evaluation of systemic and local immune responses in cancer: time for integration.

Authors:  Dmitriy W Gutkin; Michael R Shurin
Journal:  Cancer Immunol Immunother       Date:  2013-10-08       Impact factor: 6.968

8.  CD226 opposes TIGIT to disrupt Tregs in melanoma.

Authors:  Julien Fourcade; Zhaojun Sun; Joe-Marc Chauvin; Mignane Ka; Diwakar Davar; Ornella Pagliano; Hong Wang; Sofiane Saada; Carmine Menna; Rada Amin; Cindy Sander; John M Kirkwood; Alan J Korman; Hassane M Zarour
Journal:  JCI Insight       Date:  2018-07-26

9.  The role of FoxP3+ regulatory T cells and IDO+ immune and tumor cells in malignant melanoma - an immunohistochemical study.

Authors:  Satu Salmi; Anton Lin; Benjamin Hirschovits-Gerz; Mari Valkonen; Niina Aaltonen; Reijo Sironen; Hanna Siiskonen; Sanna Pasonen-Seppänen
Journal:  BMC Cancer       Date:  2021-05-29       Impact factor: 4.430

10.  Immune cell profile of sentinel lymph nodes in patients with malignant melanoma - FOXP3+ cell density in cases with positive sentinel node status is associated with unfavorable clinical outcome.

Authors:  Anita Mohos; Tímea Sebestyén; Gabriella Liszkay; Vanda Plótár; Szabolcs Horváth; István Gaudi; Andrea Ladányi
Journal:  J Transl Med       Date:  2013-02-18       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.